InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
February 27, 2018 07:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea
February 22, 2018 10:16 ET
|
InspireMD, Inc.
Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in...
InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India
February 20, 2018 09:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Feb. 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year
February 14, 2018 07:30 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Feb. 14, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD's CGuard Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists
January 31, 2018 08:31 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018
January 26, 2018 10:11 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent
January 19, 2018 10:18 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
December 07, 2017 12:23 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 07, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
December 05, 2017 13:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and Vietnam
December 04, 2017 09:45 ET
|
InspireMD, Inc.
TEL AVIV, lSRAEL, Dec. 04, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...